ArcanaBio

ArcanaBio develops solutions that analyze biomarkers in saliva, comparable to traditional blood-based diagnostics. These tests are simpler, faster, and less expensive, while avoiding the invasiveness and costs associated with blood sampling. ArcanaBio is advancing technology that can be systematically applied in the fight against antibiotic-resistant bacteria and other infectious diseases that threaten our society and infrastructure. The company has collaborated closely with the Department of Virology and Microbiology at Landspítali (National University Hospital of Iceland) in recent years, maintaining both laboratory facilities and offices within the hospital. Together, they have conducted comparative studies of ArcanaBio’s saliva-based method, including successful trials for Covid-19. The ArcanaBio team combines solid experience with a strong advisory board of domestic and international experts.